Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer

Authors

Rebecca L. Aft, Washington University School of Medicine in St. Louis
Michael J. Naughton, Washington University School of Medicine in St. Louis
Kathryn M. Trinkaus, Washington University School of Medicine in St. Louis
Katherine N. Weilbaecher, Washington University School of Medicine in St. Louis

Journal

British Journal of Cancer

Publication Date

2012

Volume

107

Issue

1

Inclusive Pages

7-11

Document Type

Open Access Publication

DOI

10.1038/bjc.2012.210

Rights and Permissions

R L Aft, et al. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer (2012) 107, 7–11. doi:10.1038/bjc.2012.210 https://www.nature.com/articles/bjc2012210 Copyright 2012 Cancer Research UK This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Recommended Citation

Aft, Rebecca L.; Naughton, Michael J.; Trinkaus, Kathryn M.; and Weilbaecher, Katherine N., "Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer." British Journal of Cancer. 107, 1. 7-11. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/4054